Skip to main content
Clinical Trials/NCT03294720
NCT03294720
Completed
Phase 1

Augmentation of ACL Reconstruction With Bone Marrow Stem Cells and Amnion Collagen Matrix Wrap: a Case Series

Andrews Research & Education Foundation1 site in 1 country10 target enrollmentJanuary 8, 2018

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
ACL - Anterior Cruciate Ligament Rupture
Sponsor
Andrews Research & Education Foundation
Enrollment
10
Locations
1
Primary Endpoint
MRI graft maturation and integration
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

The objective of this study is to evaluate the use of wrapping an ACL graft with a collagen matrix tissue wrap and injecting autologous bone marrow aspirate concentrate under the wrapping and into the graft. Investigators hypothesize that this method of augmenting ACL surgery will accelerate and improve the graft maturation and ligamentization process. Investigators propose to test this hypothesis with a series of cases of ACL reconstructions evaluated with post-operative MRI mapping sequences and validated clinical outcome measures

Detailed Description

Histologic studies have determined that graft ligamentization following anterior cruciate ligament (ACL) reconstruction may take from 6 to 18 months. (1) It has been reported that incomplete graft maturation and incorporation is one cause of clinical graft failure. Animal studies have illustrated improved tendon healing/integration in ACL models augmented with stem cell technologies. (2-4). Basic scientists theorize that optimization of stem cell treatments for tissue regeneration requires that a "regenerative triad" be employed, i.e., use of a scaffold, stem cells and growth factors. In the intra-articular environment, research has shown that a scaffold such as an amnion wrap is necessary to contain the stem cells and growth factors in close proximity to the ACL graft. (2, 4, 5) The normal, uninjured human ACL is covered by a layer of synovial tissue which contributes to the blood supply and nutrition of the native ACL. It is theorized that the lack of a synovial lining after injury and following traditional ACL reconstruction contributes to slow ligamentization and possible failure of reconstructed grafts.(5) Two studies have demonstrated accelerated maturation and ligamentization of human ACL graft augmented with point of care blood products. (6, 7) In one, leucocyte poor platelet rich plasma was injected directly into the body of the graft. (6) In the other, the platelet derived growth factors were loaded in a gelatin carrier which was wrapped around the graft. (7) In both studies accelerated and increased ligament maturation was documented compared to the controls. Collagen membranes derived from amniotic tissue have been successful to aid healing when used in difficult wounds and meniscal repair surgery. (8, 9) Investigators believe that use of a collagen based -membrane derived from amniotic tissue can be used to help reestablish the natural synovial lining of the reconstructed ACL, in effect acting as both a barrier from the synovial fluid and as a scaffold to contain autologous mesenchymal stem cells and growth factors contiguous with the graft, thus aiding and perhaps accelerating the natural maturation and ligamentization process of the implanted graft tissue. Acceleration and improvement in graft maturation and strength would be a significant advancement in sports medicine allowing safer and earlier return to sports and activity.

Registry
clinicaltrials.gov
Start Date
January 8, 2018
End Date
December 31, 2022
Last Updated
3 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Andrews Research & Education Foundation
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients between the ages of 18 and 35 who are scheduled to have anterior cruciate ligament reconstruction with autologous grafts by the principal investigator will be screened for participation in this study.
  • Patients must be willing to undergo MRI scans post -operatively at 3, 6, 9 months and 1 year.

Exclusion Criteria

  • Patients with prior procedures or significant prior injuries to the same knee are excluded. Any patient who will have difficulty obtaining internet access, does not have an active e-mail address, or is unable to comprehend study documents or give informed consent will be excluded.
  • Patient who are unable to complete MRI examinations due to claustrophobia or anxiety will be excluded.

Outcomes

Primary Outcomes

MRI graft maturation and integration

Time Frame: 3 months, 6 months, 9 months, and 12 months post-op

validated T2 star sequence which will undergo region of interest mapping to produce mean T2 values. These values have been shown to detect differences in ACL content, structure and maturation.

Secondary Outcomes

  • Changes in patient-reported pain rating(3 months, 6 months, 9 months, 12 months post-op)
  • Changes in Single Assessment Numerical Evaluation (SANE) patient ratings for function(3 months, 6 months, 9 months, 12 months post-op)
  • Marx Activity Scale Rating(3 months, 6 months, 9 months, 12 months post-op)
  • Changes in Knee injury and Osteoarthritis Outcome Score (KOOS)(3 months, 6 months, 9 months, 12 months post-op)
  • Changes in Short Form 12 (SF-12) patient ratings(3 months, 6 months, 9 months, 12 months post-op)

Study Sites (1)

Loading locations...

Similar Trials